HuScreen+TM
1+1 Mouse Trial

Rapidly progress anticancer agents using CrownBio’s unique high-throughput in vivo PDX screen

banner-eyeglasses.png

"CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease.

Leveraging our industry expertise, CrownBio's global resources help customers answer the most challenging questions about human biology. We begin with the end insight to help you achieve your goals"

Dr Jean-Pierre Wery
CEO, Crown Bioscience Inc.

CrownBio's 1+1 Mouse Trial

HuScreen+ is the first commercial in vivo screening platform to utilize a 1+1 study design to evaluate drug response using an extensive, well-characterized, clinically relevant patient-derived xenograft (PDX) collection. This exclusive 1+1 study design provides highly reproducible results, and clinically translatable data, to inform on targeted agent and combination therapy treatment approaches in a cost effective manner across a selection of different tumor types.

Highlights of HuScreen+

  • Fast and efficient in vivo screening platform
  • Under 6-month turnaround time, utilizing live PDX models with proven robust growth
  • Reliable 1+1 study design enabling a cost effective way to screen many tumor types
  • Wide spectrum of tumor types with unique mutations, genetic features, and drug responses


Request Pricing